LT3191450T - Piridono dariniai kaip transfekcijos metu pertvarkyti (ret) kinazės inhibitoriai - Google Patents

Piridono dariniai kaip transfekcijos metu pertvarkyti (ret) kinazės inhibitoriai

Info

Publication number: LT3191450T
Authority: LT; Lithuania
Prior art keywords: ret; kinase inhibitors; during transfection; pyridone derivatives; rearranged during
Prior art date: 2014-09-10

Application number

LTEP15767599.2T

Other languages

English (en)

Inventor

Michael P. Demartino

Huiping Amy Guan

Original Assignee

Glaxosmithkline Intellectual Property Development Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-10

Filing date

2015-09-09

Publication date

2019-06-10

2015-09-09 Application filed by Glaxosmithkline Intellectual Property Development Limited filed Critical Glaxosmithkline Intellectual Property Development Limited

2019-06-10 Publication of LT3191450T publication Critical patent/LT3191450T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

LTEP15767599.2T 2014-09-10 2015-09-09 Piridono dariniai kaip transfekcijos metu pertvarkyti (ret) kinazės inhibitoriai LT3191450T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CN2014086197		2014-09-10
CN2015086995		2015-08-14
PCT/IB2015/056905 WO2016038552A1 (en)	2014-09-10	2015-09-09	Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors

Publications (1)

Publication Number	Publication Date
LT3191450T true LT3191450T (lt)	2019-06-10

Family

ID=54186249

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP15767599.2T LT3191450T (lt)	2014-09-10	2015-09-09	Piridono dariniai kaip transfekcijos metu pertvarkyti (ret) kinazės inhibitoriai

Country Status (36)

Country	Link
US (4)	US9918974B2 (lt)
EP (2)	EP3191450B1 (lt)
JP (2)	JP6538154B2 (lt)
KR (1)	KR20170045350A (lt)
CN (1)	CN107074768B (lt)
AU (1)	AU2015313841B2 (lt)
BR (1)	BR112017004900A2 (lt)
CA (1)	CA2960768A1 (lt)
CL (1)	CL2017000588A1 (lt)
CO (1)	CO2017002273A2 (lt)
CR (1)	CR20170093A (lt)
CY (1)	CY1121661T1 (lt)
DK (1)	DK3191450T3 (lt)
DO (1)	DOP2017000059A (lt)
EA (1)	EA033544B1 (lt)
ES (2)	ES2816453T3 (lt)
HR (1)	HRP20190815T1 (lt)
HU (1)	HUE044604T2 (lt)
IL (1)	IL250908B (lt)
LT (1)	LT3191450T (lt)
MA (1)	MA40581A (lt)
ME (1)	ME03432B (lt)
MX (1)	MX373863B (lt)
MY (1)	MY181913A (lt)
PE (1)	PE20170705A1 (lt)
PH (1)	PH12017500425B1 (lt)
PL (1)	PL3191450T3 (lt)
PT (1)	PT3191450T (lt)
RS (1)	RS58813B1 (lt)
SG (1)	SG11201701694QA (lt)
SI (1)	SI3191450T1 (lt)
SM (1)	SMT201900304T1 (lt)
TW (1)	TWI683807B (lt)
UA (1)	UA122213C2 (lt)
UY (1)	UY36293A (lt)
WO (1)	WO2016038552A1 (lt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SMT201900203T1 (it)	2010-05-20	2019-05-10	Array Biopharma Inc	Composti macrociclici come inibitori di trk chinasi
US9879021B2 (en)	2014-09-10	2018-01-30	Glaxosmithkline Intellectual Property Development Limited	Compounds as rearranged during transfection (RET) inhibitors
HUE044604T2 (hu)	2014-09-10	2019-11-28	Glaxosmithkline Ip Dev Ltd	Piridin-származékok mint transzfekció alatt átrendezõdött (RET) kináz inhibitorok
US10202365B2 (en)	2015-02-06	2019-02-12	Blueprint Medicines Corporation	2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
SI3322706T1 (sl)	2015-07-16	2021-04-30	Array Biopharma, Inc.	Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze
BR112018008877B1 (pt)	2015-11-02	2023-01-24	Blueprint Medicines Corporation	Compostos inibidores de ret, composição farmacêutica e usos dos referidos compostos
TW201738228A (zh)	2016-03-17	2017-11-01	藍圖醫藥公司	Ｒｅｔ之抑制劑
US10227329B2 (en)	2016-07-22	2019-03-12	Blueprint Medicines Corporation	Compounds useful for treating disorders related to RET
JP2018052878A (ja) *	2016-09-29	2018-04-05	第一三共株式会社	ピリジン化合物
TWI704148B (zh)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar)	2016-10-10	2019-04-09	Array Biopharma Inc	مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
WO2018136663A1 (en)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Ret inhibitors
CA3049136C (en)	2017-01-18	2022-06-14	Array Biopharma Inc.	Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP2020519672A (ja)	2017-05-15	2020-07-02	ブループリントメディシンズコーポレイション	ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用
TWI791053B (zh)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh)	2017-10-10	2025-03-11	美商絡速藥業公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740491A1 (en)	2018-01-18	2020-11-25	Array Biopharma, Inc.	Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP6997876B2 (ja)	2018-01-18	2022-02-04	アレイバイオファーマインコーポレイテッド	Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
US11524963B2 (en)	2018-01-18	2022-12-13	Array Biopharma Inc.	Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
LT3773589T (lt)	2018-04-03	2024-02-12	Blueprint Medicines Corporation	Ret inhibitorius, skirtas naudoti vėžiui gydyti, esant ret pakitimui
ES2922314T3 (es)	2018-09-10	2022-09-13	Array Biopharma Inc	Compuestos heterocíclicos condensados como inhibidores de cinasa RET
EP4157829A1 (en)	2020-05-29	2023-04-05	Blueprint Medicines Corporation	Solid forms of pralsetinib
CN115803316B (zh) *	2020-07-23	2024-12-06	深圳晶泰科技有限公司	吡啶酮类化合物及其制备方法和应用
CN119768181A (zh)	2022-08-24	2025-04-04	东丽株式会社	用于癌的治疗和/或预防的药品

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ505844A (en)	1997-12-22	2003-10-31	Bayer Ag	Inhibition of raf kinase using substituted heterocyclic ureas
US20070244120A1 (en)	2000-08-18	2007-10-18	Jacques Dumas	Inhibition of raf kinase using substituted heterocyclic ureas
US20120046290A1 (en)	1997-12-22	2012-02-23	Jacques Dumas	Inhibition of p38 kinase activity using substituted heterocyclic ureas
DE1041982T1 (de)	1997-12-22	2001-06-07	Bayer Corp., Pittsburgh	HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTEN HETEROCYCLISCHEN HARNSTOFFEN
EE200200065A (et)	1999-08-12	2003-04-15	Pharmacia Italia S.P.A.	3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon
JP2004517840A (ja) *	2000-11-27	2004-06-17	フアルマシア・イタリア・エツセ・ピー・アー	フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用
DE10201764A1 (de)	2002-01-18	2003-07-31	Bayer Cropscience Ag	Substituierte 4-Aminopyridin-Derivate
PE20040522A1 (es)	2002-05-29	2004-09-28	Novartis Ag	Derivados de diarilurea dependientes de la cinasa de proteina
AU2003264386A1 (en)	2002-09-10	2004-04-30	Kyorin Pharmaceutical Co., Ltd.	4-(substituted aryl)-5-hydroxyisoquinolinone derivative
RU2006108864A (ru)	2003-08-22	2007-09-27	Берингер Ингельхайм Фармасьютиклз, Инк. (Us)	Способы лечения хронического обструктивного заболевания легких (хозл) и легочной гипертензии
TW200530236A (en) *	2004-02-23	2005-09-16	Chugai Pharmaceutical Co Ltd	Heteroaryl phenylurea
BRPI0519424B8 (pt) *	2004-12-28	2021-05-25	Athenex Inc	compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
US7968574B2 (en)	2004-12-28	2011-06-28	Kinex Pharmaceuticals, Llc	Biaryl compositions and methods for modulating a kinase cascade
GB0507575D0 (en) *	2005-04-14	2005-05-18	Novartis Ag	Organic compounds
US8247556B2 (en) *	2005-10-21	2012-08-21	Amgen Inc.	Method for preparing 6-substituted-7-aza-indoles
TW200804349A (en) *	2005-12-23	2008-01-16	Kalypsys Inc	Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
ES2500165T3 (es)	2006-06-29	2014-09-30	Kinex Pharmaceuticals, Llc	Composiciones de biarilo y métodos para modular una cascada de quinasas
WO2008033562A2 (en) *	2006-09-15	2008-03-20	Xcovery, Inc.	Kinase inhibitor compounds
US7977338B2 (en) *	2006-10-16	2011-07-12	Novartis Ag	Phenylacetamides being FLT3 inhibitors
PL2848610T3 (pl) *	2006-11-15	2018-01-31	Ym Biosciences Australia Pty	Inhibitory aktywności kinazy
CN102470127A (zh)	2009-08-19	2012-05-23	埃姆比特生物科学公司	联芳基化合物和其使用方法
US9073895B2 (en)	2010-12-16	2015-07-07	Boehringer Ingelheim International Gmbh	Biarylamide inhibitors of leukotriene production
US8937071B2 (en)	2013-03-15	2015-01-20	Glaxosmithkline Intellectual Property Development Limited	Compounds as rearranged during transfection (RET) inhibitors
EA029296B1 (ru)	2013-03-15	2018-03-30	Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	Пиридиновые производные в качестве ингибиторов реаранжированной в процессе трансфекции (ret) киназы
HUE044604T2 (hu)	2014-09-10	2019-11-28	Glaxosmithkline Ip Dev Ltd	Piridin-származékok mint transzfekció alatt átrendezõdött (RET) kináz inhibitorok
US9879021B2 (en)	2014-09-10	2018-01-30	Glaxosmithkline Intellectual Property Development Limited	Compounds as rearranged during transfection (RET) inhibitors

2015
- 2015-09-09 HU HUE15767599 patent/HUE044604T2/hu unknown
- 2015-09-09 JP JP2017513450A patent/JP6538154B2/ja not_active Expired - Fee Related
- 2015-09-09 EP EP15767599.2A patent/EP3191450B1/en active Active
- 2015-09-09 LT LTEP15767599.2T patent/LT3191450T/lt unknown
- 2015-09-09 AU AU2015313841A patent/AU2015313841B2/en not_active Ceased
- 2015-09-09 SI SI201530720T patent/SI3191450T1/sl unknown
- 2015-09-09 MY MYPI2017700782A patent/MY181913A/en unknown
- 2015-09-09 WO PCT/IB2015/056905 patent/WO2016038552A1/en not_active Ceased
- 2015-09-09 SG SG11201701694QA patent/SG11201701694QA/en unknown
- 2015-09-09 RS RS20190559A patent/RS58813B1/sr unknown
- 2015-09-09 UA UAA201703478A patent/UA122213C2/uk unknown
- 2015-09-09 HR HRP20190815TT patent/HRP20190815T1/hr unknown
- 2015-09-09 DK DK15767599.2T patent/DK3191450T3/da active
- 2015-09-09 CA CA2960768A patent/CA2960768A1/en not_active Abandoned
- 2015-09-09 ES ES19160650T patent/ES2816453T3/es active Active
- 2015-09-09 KR KR1020177009237A patent/KR20170045350A/ko not_active Ceased
- 2015-09-09 MA MA040581A patent/MA40581A/fr unknown
- 2015-09-09 SM SM20190304T patent/SMT201900304T1/it unknown
- 2015-09-09 CR CR20170093A patent/CR20170093A/es unknown
- 2015-09-09 PL PL15767599T patent/PL3191450T3/pl unknown
- 2015-09-09 ME MEP-2019-136A patent/ME03432B/me unknown
- 2015-09-09 BR BR112017004900A patent/BR112017004900A2/pt not_active IP Right Cessation
- 2015-09-09 MX MX2017003114A patent/MX373863B/es active IP Right Grant
- 2015-09-09 PT PT15767599T patent/PT3191450T/pt unknown
- 2015-09-09 EA EA201790546A patent/EA033544B1/ru not_active IP Right Cessation
- 2015-09-09 CN CN201580058320.5A patent/CN107074768B/zh not_active Expired - Fee Related
- 2015-09-09 EP EP19160650.8A patent/EP3517526B1/en active Active
- 2015-09-09 PE PE2017000417A patent/PE20170705A1/es unknown
- 2015-09-09 ES ES15767599T patent/ES2725704T3/es active Active
- 2015-09-09 US US15/509,613 patent/US9918974B2/en not_active Expired - Fee Related
- 2015-09-10 UY UY0001036293A patent/UY36293A/es unknown
- 2015-09-10 TW TW104129876A patent/TWI683807B/zh not_active IP Right Cessation
2017
- 2017-03-02 IL IL250908A patent/IL250908B/en active IP Right Grant
- 2017-03-07 PH PH12017500425A patent/PH12017500425B1/en unknown
- 2017-03-07 CO CONC2017/0002273A patent/CO2017002273A2/es unknown
- 2017-03-07 DO DO2017000059A patent/DOP2017000059A/es unknown
- 2017-03-09 CL CL2017000588A patent/CL2017000588A1/es unknown
2018
- 2018-01-23 US US15/877,524 patent/US10111866B2/en not_active Expired - Fee Related
- 2018-09-28 US US16/145,271 patent/US10292975B2/en not_active Expired - Fee Related
2019
- 2019-04-05 US US16/376,858 patent/US10709695B2/en not_active Expired - Fee Related
- 2019-05-09 CY CY20191100502T patent/CY1121661T1/el unknown
- 2019-05-31 JP JP2019102776A patent/JP6728447B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR20170045350A (ko)	2017-04-26
MX373863B (es)	2020-03-26
UA122213C2 (uk)	2020-10-12
PH12017500425A1 (en)	2017-07-31
PT3191450T (pt)	2019-05-29
ES2725704T3 (es)	2019-09-26
US20190247382A1 (en)	2019-08-15
PE20170705A1 (es)	2017-05-21
IL250908A0 (en)	2017-04-30
CO2017002273A2 (es)	2017-06-20
MX2017003114A (es)	2017-11-15
EA201790546A1 (ru)	2017-07-31
WO2016038552A1 (en)	2016-03-17
PH12017500425B1 (en)	2017-07-31
CA2960768A1 (en)	2016-03-17
MA40581A (fr)	2019-04-10
US10709695B2 (en)	2020-07-14
UY36293A (es)	2016-04-01
TW201625534A (en)	2016-07-16
CN107074768B (zh)	2019-12-10
BR112017004900A2 (pt)	2017-12-12
DK3191450T3 (da)	2019-05-20
EP3191450A1 (en)	2017-07-19
JP2019163316A (ja)	2019-09-26
AU2015313841B2 (en)	2018-03-08
CL2017000588A1 (es)	2017-10-06
CN107074768A (zh)	2017-08-18
AU2015313841A1 (en)	2017-03-23
US20180147194A1 (en)	2018-05-31
SG11201701694QA (en)	2017-04-27
ME03432B (me)	2020-01-20
CR20170093A (es)	2017-07-17
JP6728447B2 (ja)	2020-07-22
US10292975B2 (en)	2019-05-21
JP6538154B2 (ja)	2019-07-03
US9918974B2 (en)	2018-03-20
HUE044604T2 (hu)	2019-11-28
TWI683807B (zh)	2020-02-01
PL3191450T3 (pl)	2019-08-30
EP3517526B1 (en)	2020-08-19
EP3191450B1 (en)	2019-04-10
RS58813B1 (sr)	2019-07-31
ES2816453T3 (es)	2021-04-05
JP2017527578A (ja)	2017-09-21
IL250908B (en)	2020-11-30
US20190022078A1 (en)	2019-01-24
SMT201900304T1 (it)	2019-07-11
EP3517526A1 (en)	2019-07-31
HRP20190815T1 (hr)	2019-07-12
MY181913A (en)	2021-01-14
US20170340617A1 (en)	2017-11-30
US10111866B2 (en)	2018-10-30
SI3191450T1 (sl)	2019-07-31
EA033544B1 (ru)	2019-10-31
CY1121661T1 (el)	2020-07-31
DOP2017000059A (es)	2017-03-31

Publication	Publication Date	Title
IL250908A0 (en)	2017-04-30	Pyridone derivatives as ret kinase inhibitors
IL250923B (en)	2021-04-29	New compounds as ret inhibitors
IL241161A0 (en)	2015-11-30	History of pyridine as inhibitors of rearrangement during transfection (ret) kinases
PL3218378T3 (pl)	2020-10-19	Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych
EP3131900A4 (en)	2017-11-15	Heterocyclic kinase inhibitors
ZA201701841B (en)	2019-08-28	Macrocyclic lrrk2 kinase inhibitors
AP2016009661A0 (en)	2016-12-31	Quinolizinone derivatives as pi3k inhibitors
IL258438B (en)	2020-06-30	2-Aminoquinoline derivatives as p70s6 kinase inhibitors
IL252866B (en)	2020-09-30	History of imidazopyridazine as pi3k beta inhibitors
IL258690A (en)	2018-06-28	Pyridone derivatives and their use as kinase inhibitors
PL2958531T3 (pl)	2017-01-31	Metoda ustawiania parametrów impulsu laserowego związanych z energią
IL248568B (en)	2019-03-31	A process for the preparation of dihydroisoxazole derivatives
GB201416351D0 (en)	2014-10-29	Heterocyclic derivatives
ZA201506309B (en)	2017-11-29	Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors
TH1501005474A (th)	2017-01-04	อนุพันธ์ไพริดีนในรูปสารยับยั้งไคเนสถูกจัดเรียงใหม่ในระหว่างการทรานส์เฟคชั่น (ret)
HK1237342A1 (en)	2018-04-13	Compounds as rearranged during transfection (ret) inhibitors
HK1237342B (en)	2021-01-29	Compounds as rearranged during transfection (ret) inhibitors
GB201404570D0 (en)	2014-04-30	Macrocyclic kinase inhibitors
GB201404555D0 (en)	2014-04-30	Macrocyclic kinase inhibitors